Your Newborn's Blood Count and Down Syndrome: What the Numbers Mean and Why the Record Matters

What three 2026 studies of transient abnormal myelopoiesis and childhood leukaemia in Down syndrome say for families

Babies born with Down syndrome very often have unusual blood counts in their first days, and a small number have a temporary condition called transient abnormal myelopoiesis that can occasionally turn into leukaemia within a few years. Three studies published in 2026 sort out which findings should worry families and which should not, and point to something simple: the most valuable thing a newborn team can do about leukaemia risk is to write down carefully what it finds.

Why doctors check a newborn's blood when a baby has Down syndrome

Almost every baby born with an extra copy of chromosome 21 has a blood count that looks unusual. The platelets — the cells that help blood clot — may be low or high, the red cells may be larger than average, and the proportions of different white cells are often shifted. Most of these changes are mild, settle on their own, and matter mainly because they can be mistaken for something worse [1].

One condition, though, is unique to babies with Down syndrome and needs to be recognised: transient abnormal myelopoiesis, usually shortened to TAM. In TAM, immature blood cells known as blasts appear in the bloodstream in unusually large numbers, and the baby's liver often becomes enlarged. It happens because a gene called GATA1, which normally helps blood cells mature properly, has picked up a change before birth. "Transient" is the important word: in most babies the abnormal cells disappear on their own over weeks to months without any treatment.

Doctors take TAM seriously less for what it does in the newborn nursery — although it can occasionally make a baby very ill — than for what it can do later. The same abnormal cells can persist quietly and, in a minority of children, acquire further changes and become a form of leukaemia called myeloid leukaemia of Down syndrome. That connection, the same faulty gene in both the newborn condition and the later leukaemia, was established more than twenty years ago [2].

What families used to be told, and how that changed

For a long time families were told very little that was precise, because the numbers were not available. That changed with two carefully conducted North American studies that followed babies from the moment TAM was diagnosed.

In the first, 48 infants with Down syndrome and this newborn condition were followed closely. Most cleared the abnormal cells from their blood by themselves — 89% did so — and about three-quarters had completely normal blood counts afterwards. But 17% died early, and those deaths were linked to a very high white cell count and to signs of liver strain. About 19% went on to develop leukaemia, on average around 20 months later [3].

The second followed 135 newborns and produced the rough guide many doctors still carry in their heads. Babies with neither an enlarged liver nor life-threatening symptoms did very well, with survival around 92%; those with an enlarged liver alone were in between, at about 77%; and babies with both had survival closer to 51%. Among those who simply needed watching, the abnormal blood cells cleared after about 36 days on average and the remaining signs after about 49 days. Roughly 16% later developed leukaemia, typically a little over a year after birth [4].

A study in the United Kingdom then added something uncomfortable but useful. Researchers examined the blood of 200 newborns with Down syndrome in detail. Nearly all — 97.5% — had at least some blasts. Standard laboratory testing found a GATA1 change in 8.5%. But when a far more sensitive technique was used on babies whose standard test had been negative, about one in five turned out to have a small hidden clone of abnormal cells, and nothing about how these babies looked or how their counts appeared set them apart [5]. Doctors call this "silent TAM": a healthy-looking baby with an unremarkable blood film can still be carrying the change.

The three studies behind this article

The first of the 2026 reports comes from Japan, from a national study called TAM-10 that followed babies with this condition prospectively across many hospitals; researchers looked at every baby's platelet count at diagnosis and asked what a high count actually means [6].

The second comes from the Children's Oncology Group in North America, from a trial called AAML1531 that enrolled only children with Down syndrome who had developed leukaemia, aged three months to four years, across the group's hospitals [7].

The third comes from Türkiye, where fourteen hospitals pooled the records of 53 children with Down syndrome who developed myeloid leukaemia over fourteen years [8]. Together they follow one thread: from the newborn blood count, through treatment, to what happens years later.

A very high platelet count sounds alarming but usually is not

Parents are often told that TAM is a condition in which platelets are low, so a count that comes back extremely high can be frightening — especially because in adults, very high platelet counts are associated with dangerous blood clots.

The Japanese study looked at all 167 babies in its cohort and found platelet counts varied enormously. About 4% had counts above 1,000 (in the units laboratories use, where a typical newborn sits between 150 and 450), a further 20% were between 450 and 999, about 31% were normal, and 45% were below 150. The highest count in the group was 1,806 [6].

The reassuring finding is the important one. Not a single baby in the study had a blood clot, including those with the very highest platelet counts. Only one of these babies was given low-dose aspirin. And the babies with high counts were no more likely to die early, to die later, or to go on to develop leukaemia than babies whose counts were normal or low. In most cases the platelet count rose to a peak about a month after diagnosis and then came down on its own, without any treatment [6]. Some babies then passed through a phase of low platelets that also corrected itself over roughly three months.

Babies with higher platelet counts did tend to have higher white cell counts, more blasts, and more liver involvement, and the researchers were able to link the pattern to the specific type of GATA1 change the baby carried — a link that fits with earlier work showing that different versions of the change behave differently [9]. But a number on its own is not a reason to treat. What did matter was the opposite picture: platelets that stayed low well beyond the expected window were seen only in babies who became seriously unwell or whose condition progressed.

When leukaemia does develop, more chemotherapy is not the answer

Children with Down syndrome who develop myeloid leukaemia usually do remarkably well. Their leukaemia cells are unusually sensitive to chemotherapy, so doctors have spent two decades carefully giving less treatment rather than more, to spare children the infections and other harms of intensive therapy. One major trial achieved five-year survival of 93% while doing exactly that [10].

The AAML1531 trial asked whether a test done after the first round of chemotherapy — looking for tiny numbers of leftover leukaemia cells — could decide who needed stronger treatment. Of 280 children enrolled, 41 had leftover cells detected and were given the much more intensive chemotherapy normally used for children without Down syndrome. It did not help: survival without the leukaemia returning was about 80.5% at two years, essentially the same as the roughly 76% seen historically with gentler treatment [7]. The harms were clear: serious fever with low white cells occurred in about 32% of these children during one course, against under 4% on the gentler arm, and serious bloodstream infections rose from none to about 10%. An earlier report from the same trial had already shown that cutting treatment back too far was also harmful [11].

What did predict which children would relapse was genetic. In the third of children whose leukaemia cells had been sequenced, those carrying a change in any of four particular genes had survival without relapse of about 50% at two years, compared with about 91% for those without [7]. That four-gene pattern had first been identified in Japanese studies [12], and its confirmation in a North American trial means it is likely to shape how children are treated in future. For the small number of children whose leukaemia returns despite everything, outcomes remain poor, with roughly one in five surviving three years [13] — which is precisely why researchers want better ways to identify them in advance rather than better ways to give more of the same drugs.

Why the newborn record matters years later

The Turkish study explains why all of this can fall apart in ordinary practice. Among the 53 children, those whose leukaemia was the Down syndrome-specific type had five-year survival of about 84%, while those who happened to develop the ordinary kind of leukaemia seen in other children had survival closer to 53% [8]. Telling the two apart therefore matters a great deal, because they need different treatment.

But the GATA1 test had been done in only about 23% of these children, and only 11% had a recorded history of TAM as a newborn — far below the 37% to 44% reported elsewhere [8]. Given how common silent TAM is, a missing newborn history almost certainly means nobody looked, rather than that nothing happened. A line in a discharge summary written when a baby is a week old can, years later, be what tells an oncologist which disease they are treating.

What this means for your baby

If your baby has Down syndrome and an abnormal blood count, the likeliest outcome by a wide margin is that it will settle without treatment. If TAM is diagnosed, treatment is usually given only when the baby is actually unwell — most often when an enlarged liver is affecting breathing or heart function — and not because of a number on a report. A high platelet count is not, on this evidence, something to treat or to fear [6]. It is entirely reasonable to ask your team three questions: has a GATA1 test been done, is TAM written in the discharge summary, and what blood-test follow-up is planned over the next four years.

What researchers are working on next

Three efforts are under way. The first is finding out whether testing every newborn with Down syndrome for the GATA1 change, including hidden clones, is practical at scale — which would allow risk to be estimated from birth rather than from the moment leukaemia appears [5]. The second is bringing the four-gene test forward, so children unlikely to benefit from stronger chemotherapy can be offered something genuinely different [7]. The third is developing treatments aimed at the abnormal GATA1 protein itself, including antibody-based drugs directed at markers found only on these leukaemia cells; early laboratory work is promising [14], and Down syndrome and leukaemia is now a focused international research effort [15]. None of this changes what families can do today, which remains straightforward: make sure the first blood count is taken, understood, and written down.

Related: platelet transfusions in newborns and genomic newborn screening.

References

  1. Bhatnagar N, Roberts I. Hematological conditions in infants with trisomy 21. Neoreviews. 2026;27(1):e25–e38. doi:10.1542/neo.27-1-086 ↩
  2. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101(11):4301–4304. doi:10.1182/blood-2003-01-0013 ↩
  3. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006;107(12):4606–4613. doi:10.1182/blood-2005-06-2448 ↩
  4. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011;118(26):6752–6759. doi:10.1182/blood-2011-04-350017 ↩
  5. Roberts I, Alford K, Hall G, et al. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood. 2013;122(24):3908–3917. doi:10.1182/blood-2013-07-515148 ↩
  6. Saida S, Toki T, Shimizu R, et al. Clinical and molecular characterization of thrombocytosis in transient abnormal myelopoiesis. Leukemia. 2026;40(7):1574–1578. doi:10.1038/s41375-026-02960-z ↩
  7. Berman JN, Verma A, Viola S, et al. Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease. Blood Adv. 2026;10(5):1576–1586. doi:10.1182/bloodadvances.2025017837 ↩
  8. Düzenli Kar Y, Ören H, Sezgin Evim M, et al. Outcomes of Down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association. Ann Hematol. 2026;105(10):422. doi:10.1007/s00277-026-07245-0 ↩
  9. Kanezaki R, Toki T, Terui K, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010;116(22):4631–4638. doi:10.1182/blood-2010-05-282426 ↩
  10. Taub JW, Berman JN, Hitzler JK, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017;129(25):3304–3313. doi:10.1182/blood-2017-01-764324 ↩
  11. Hitzler J, Alonzo T, Gerbing R, et al. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021;138(23):2337–2346. doi:10.1182/blood.2021012206 ↩
  12. Sato T, Yoshida K, Toki T, et al. Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms. Blood. 2024;143(25):2627–2643. doi:10.1182/blood.2023022247 ↩
  13. Raghuram N, Hasegawa D, Nakashima K, et al. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome. Blood Adv. 2023;7(21):6532–6539. doi:10.1182/bloodadvances.2022009381 ↩
  14. Verboon LJ, Barwe SP, Tavenner M, et al. DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia. Blood Adv. 2026;10(12):4120–4133. doi:10.1182/bloodadvances.2025018830 ↩
  15. Baruchel A, Bourquin JP, Crispino J, et al. Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023;108(10):2570–2581. doi:10.3324/haematol.2023.283225 ↩